Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2025 | $75.00 | Outperform | Wolfe Research |
| 10/7/2025 | $125.00 | Buy | Goldman |
| 8/20/2025 | $123.00 | Overweight | Wells Fargo |
| 6/23/2025 | $110.00 | Buy | TD Cowen |
| 3/5/2025 | $74.00 | Buy | Stifel |
| 12/2/2024 | $74.00 | Buy | Stifel |
| 12/2/2024 | $72.00 | Outperform | Robert W. Baird |
| 9/3/2024 | $70.00 | Buy | H.C. Wainwright |
8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)
S-8 - SOLENO THERAPEUTICS INC (0001484565) (Filer)
10-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.From approval on March 26, 2025 through December 31, 2025, Soleno reports: 1,250 patien
REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourth quarter and full-year 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, February 25, 2026. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, February 25, 2026Time:4:30 PM Eastern TimeUnited States:1-800-717-1738Internation
Wolfe Research initiated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $75.00
Goldman initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $125.00
Wells Fargo initiated coverage of Soleno Therapeutics with a rating of Overweight and set a new price target of $123.00
SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.From approval on March 26, 2025 through December 31, 2025, Soleno reports: 1,250 patien
REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourth quarter and full-year 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, February 25, 2026. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, February 25, 2026Time:4:30 PM Eastern TimeUnited States:1-800-717-1738Internation
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the third quarter ended September 30, 2025 and provided an update on the U.S. launch of VYKATTM XR. Third Quarter 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three months ended September 30, 2025 was $66.0 million and the Company achieved profitability with positive net income of $26.0 million for the third quarter.From approval on March 26, 2025 through September 30, 2025, Soleno reports: 1,043 patient start form
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c
REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno's Board nearly 30 years of CFO-level experience and has played a key role in numerous successful product launches, financings, and M&A transactions within the life sciences sector. With the addition of Mr. Hahn, the Soleno Board increases to seven seats. "I am very pleased to welcome Mark to the
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "Inclusion in the Russell indexes is a significant milestone and reflects the meaningful progress Soleno has made in advancing our lead candidate DCCR (diazoxide choline) extended-release ta